NCT00356759View on ClinicalTrials.gov

Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

January 31, 2010

Study Completion Date

February 28, 2010

Conditions

Atrial FibrillationHeart Valve DiseasesVenous Thrombosis

Interventions

DRUG

Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times

Warfarin is dosed according to INR to maintain INR 2.0-3.0 or for mechanical mitral valves or mechanical aortic valves with atrial fibrillation INR 2.5-3.5

Trial Locations (1)

L8L 2X2

HHS - General Hospital, Thrombosis Service, Hamilton

All Listed Sponsors

collaborator

The Physicians' Services Incorporated Foundation

OTHER

lead

Hamilton Health Sciences Corporation

OTHER

NCT00356759 - Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients | Biotech Hunter | Biotech Hunter